Efgartigimod Emerging Drug Insight

“Efgartigimod Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about efgartigimod for thrombocytopenia in the seven major markets. A detailed picture of the efgartigimod for thrombocytopenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the efgartigimod for thrombocytopenia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the efgartigimod market forecast analysis for thrombocytopenia in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in thrombocytopenia.

Drug Summary

Efgartigimod (ARGX-113) is an investigational therapy for IgG-mediated autoimmune diseases and was designed to exploit the natural interaction between IgG antibodies and the recycling receptor FcRn Argenx, designed efgartigimod to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications, namely multiple sclerosis, ITP, systemic lupus erythematosus, myasthenia gravis, and skin-blistering diseases.

Efgartigimod is the Fc-portion of an IgG1 antibody modified by the Argenx proprietary ABDEG technology to increase its affinity for FcRn beyond normal IgG antibodies. As a result, efgartigimod blocks antibody recycling through FcRn binding and leads to fast depletion of the autoimmune disease-causing IgG autoantibodies. The development work on efgartigimod is conducted in close collaboration with Prof. E. Sally Ward (University of Texas Southwestern Medical and Texas A&M University Health Science Center, a part of Texas A & M University (TAMHSC)). The drug is currently in Phase III trial for adult patients with primary ITP. The company is currently investigating efgartigimod for intravenous (IV) use and initiated a trial for SC administration enabled by Halozyme’s ENHANZE drug delivery technology.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the efgartigimod description, mechanism of action, dosage and administration, research and development activities in thrombocytopenia.
• Elaborated details on efgartigimod regulatory milestones and other development activities have been provided in this report.
• The report also highlights the efgartigimod research and development activities in thrombocytopenia across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around efgartigimod.
• The report contains forecasted sales of for thrombocytopenia till 2032.
• Comprehensive coverage of the late-stage emerging therapies for thrombocytopenia.
• The report also features the SWOT analysis with analyst views for efgartigimod in thrombocytopenia.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Efgartigimod Analytical Perspective by DelveInsight

In-depth Efgartigimod Market Assessment

This report provides a detailed market assessment of efgartigimod for thrombocytopenia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

Efgartigimod Clinical Assessment

The report provides the clinical trials information of efgartigimod for thrombocytopenia covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for thrombocytopenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence efgartigimod dominance.
• Other emerging products for thrombocytopenia are expected to give tough market competition to efgartigimod and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of efgartigimod in thrombocytopenia.
• Our in-depth analysis of the forecasted sales data of efgartigimod from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the efgartigimod in thrombocytopenia.

Key Questions

• What is the product type, route of administration and mechanism of action of efgartigimod?
• What is the clinical trial status of the study related to efgartigimod in thrombocytopenia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the efgartigimod development?
• What are the key designations that have been granted to efgartigimod for thrombocytopenia?
• What is the forecasted market scenario of efgartigimod for thrombocytopenia?
• What are the forecasted sales of efgartigimod in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to efgartigimod for thrombocytopenia?
• Which are the late-stage emerging therapies under development for the treatment of thrombocytopenia?